Registration Open and Morning Coffee07:30
INNOVATIVE APPROACHES TO THE CHALLENGES OF SOLID TUMOURS
Tumour Specific Immunogene Therapy to Deliver Protein Therapeutics to Solid Tumour Microenvironments
The tumour-specific immunogene platform (T-SIGn) has been designed to deliver protein therapeutics selectively to tumor microenvironments following systemic dosing and is moving into Phase 2 clinical testing. Novel antibody fragments have been expressed and validated, including single, bispecific, and biparatopic ScFv, and single and tandem VHH. The functionality of immune checkpoint inhibitors and immune inhibitors will be presented. Perspectives on the expression of combination therapeutics with fragment antibodies and other immune modulatory proteins within the solid tumour microenvironment will be discussed.
Local Secretion of Immune Active Proteins for Direct and Bystander Tumour Killing
Whilst striking success has been seen using CAR T cells to treat leukaemia and other cancers, the majority of solutions are autologous leading to high production costs and logistical challenges. Vg9Vd2-gdT cells are a versatile, non-alloreactive chassis for cellular immunotherapy, possessing potent antibody-dependent cellular cytotoxicity (ADCC) capacity, a tissue-tropic homing profile, and a range of innate tumour-sensing receptors minimizing the likelihood of tumour escape. OPS-gd is a cell therapy platform harnessing these properties, secreting tumour-targeting opsonins and armouring cytokines. OPS-gd cells show equivalent cytotoxicity but superior exhaustion phenotype to CAR-abT cells, recruitment of ADCC-competent bystanders, and in vivo efficacy against patient-derived osteosarcoma.
Session Break to Transition into Plenary Keynote10:00
PLENARY KEYNOTE SESSION
Benchmarking the Impact of AI Biologics Discovery and Optimisation for Pharma
The biologics landscape is rapidly changing with the number of AI-enabled biologics in pre-clinical and clinical stages estimated to be 50-60 (1). This change is driven by the increase in enterprise software solutions to capture and store data, augmented discovery workflows, improvements in machine learning technology, and advances in computing power. Augmented biologics discovery has the potential to revolutionize biologics discovery, yet information of how in silico technologies perform, versus traditional discovery platforms is scarce. At PEGS Europe, we will present current in silico biologics design and optimisation technologies, with a focus on our internal efforts to benchmark the impact of combining novel in silico technologies with our existing biologics discovery platforms.
Coffee Break in the Exhibit Hall with Poster Viewing11:00
INNOVATIVE APPROACHES TO THE CHALLENGES OF SOLID TUMOURS
AI-Based Target and Antibody Discovery from Patient Tumour Profiles
Patient tumours contain anti-tumour antibodies but might not have sufficient abundance and correct Fc to cure the tumours. GV20 uses bioinformatics and AI to decode natural B-cell responses from large cohorts of patient tumours to uncover novel targets and antibodies simultaneously. It already brought a first-in-class antibody against a novel innate checkpoint to Ph1 clinical trial in the US.
The Influence of DM1, MMAE, and MMAF on Biodistribution and Preclinical Therapeutic Efficacy of Affibody-Based Drug Conjugates
Affibody molecules are small engineered alternative scaffold affinity proteins that can be site-specifically loaded with cytotoxic drugs to create homogenous conjugates with a desired drug-to-carrier ratio. The presentation will explore the targeting of HER2 and HER3 with affibody-based drug conjugates. It will also describe the impact on biodistribution and in vivo cytotoxic efficacy of drug conjugates loaded with auristatin and maytansine-derived payloads.
Galaxy® is our proprietary technology platform. Our ‘glass spleen’ approach incorporates the learnings of the in vivo selection process and allows us to access a far greater fraction of relevant antibody space. Based on the principle of ‘smart randomness’, it harnesses the incredible diversity found within human B cells. Furthermore, the design provides the potential to rapidly generate cheap to manufacture bispecifics without the need for any special technology or engineering.
Luncheon Presentation (Sponsorship Opportunity Available) or Enjoy Lunch on Your Own13:20
ADVANCES IN DISCOVERY AND ENGINEERING OF ANTIBODIES FOR NON-CANCER TARGETS
Discovery of Broadly-Neutralizing Antibodies against Coronaviruses
The potential for future coronavirus outbreaks and ongoing mutations in SARS-CoV-2 highlight the need to broadly target this group of pathogens. Here, we used an epitope-agnostic approach to identify two groups of monoclonal antibodies that target distinct regions of the spike protein and broadly neutralize diverse coronaviruses. Top neutralizers from both antibody classes neutralized all SARS-CoV-2 variants of concern tested including the Omicron subvariant XBB.1.5, inhibited fusion mediated by SARS-CoV-2 spike, and limited disease caused by SARS-CoV-2 in a Syrian hamster model. This two-step approach of isolating rare neutralizing mAbs against cryptic targets is highly relevant for pandemic prevention and the development of therapeutic tools against emerging pathogens.
Sponsored Presentation (Opportunity Available)15:35
Refreshment Break in the Exhibit Hall with Poster Viewing16:05
A Patient-First Approach to Discover First-in-Class Antibody Therapeutics
Identifying genuinely novel targets that have immense therapeutic potential is an increasing challenge across central nervous system diseases. Alchemab addresses this challenge by truly disrupting the target discovery process - simply put, we let the patient select the best targets. We have discovered novel disease-relevant targets through our proprietary platform that searches for protective auto-antibodies in patients who are resistant to disease.
Advancing Snake Envenomation Treatment: Designing the Next Generation of Antivenoms
Snake envenomation kills over 100,000 people annually and cripples three times as many. Current treatment relies on animal-derived serum, which, although life-saving presents many drawbacks, including lack of standardisation, a low proportion of neutralising antibodies, and serum sickness from injecting grams of animal protein. Therefore, it is crucial to modernise snakebite treatment. This presentation will show the ongoing efforts in developing the new generation of antivenoms and their associated challenges.
Advancing Brain Shuttle-Enabled Therapeutics for Efficient Delivery to CNS -Translation to Primates
Brain delivery across blood-brain barrier (BBB) is a major hurdle in the development of biological therapeutics for CNS disorders. We developed TXP1 brain shuttle based on anti-TfR1 antibody that can be fused to any therapeutic payload. In monkeys, TXP1 demonstrated ~35-fold improved brain penetration over the control, reaching up to 7.5% brain/plasma ratio. TXP1 showed to be safe and provided brain-specific delivery with no accumulation in other organs and had long-lasting brain PK, essential for efficacious CNS therapies.
Development of Autoregulating FVIII-Mimetic Bispecific Antibodies to Reduce Risk of Prothrombotic Events in Treatment of Haemophilia A
Close of Emerging Targets and Therapeutic Approaches Conference19:00
- Antibody-Based Therapies
- Emerging Targets & Approaches
- Membrane Protein Targets
- Safety & Efficacy of Bispecifics
- Advancing Bispecifics
- Engineering Bispecifics
- Optimisation & Developability
- Analytical Characterisation
- Protein Stability & Formulation